Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) ROC %: 0.65% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603392 Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
53 GF Score
Price ¥29.20
GF Value ¥42.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Beijing Wantai Biological Pharmacy Enterprise Co ROC %?

Beijing Wantai Biological Pharmacy Enterprise Co SHSE:603392 +0.17% 53 ROC % is 0.65% as of Mar. 2026. GuruFocus rates SHSE:603392 with a GF Score™ of 53/100 and a GF Value™ of ¥42.09 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Beijing Wantai Biological Pharmacy Enterprise Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 0.65%.

As of today (2026-07-28), Beijing Wantai Biological Pharmacy Enterprise Co's WACC % is 12.00%. Beijing Wantai Biological Pharmacy Enterprise Co's ROC % is -3.50% (calculated using TTM income statement data). Beijing Wantai Biological Pharmacy Enterprise Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Beijing Wantai Biological Pharmacy Enterprise Co  (SHSE:603392) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Beijing Wantai Biological Pharmacy Enterprise Co's WACC % is 12.00%. Beijing Wantai Biological Pharmacy Enterprise Co's ROC % is -3.50% (calculated using TTM income statement data). Beijing Wantai Biological Pharmacy Enterprise Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Beijing Wantai Biological Pharmacy Enterprise Co ROC % Related Terms


Beijing Wantai Biological Pharmacy Enterprise Co ROC % Historical Data

* Premium members only.

The historical data trend for Beijing Wantai Biological Pharmacy Enterprise Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Wantai Biological Pharmacy Enterprise Co ROC % Chart

Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.72 104.55 21.96 0.03 -4.41

Beijing Wantai Biological Pharmacy Enterprise Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -4.02 -2.41 -7.88 0.65
SHSE:603392
53GF Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Wantai Biological Pharmacy Enterprise Co ROC % Calculation

Beijing Wantai Biological Pharmacy Enterprise Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-426.405 * ( 1 - 13.92% )/( (8036.155 + 8613.838)/ 2 )
=-367.049424/8324.9965
=-4.41 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14689.396 - 1755.336 - ( 4897.905 - max(0, 2012.072 - 8374.875+4897.905))
=8036.155

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14044.057 - 1548.396 - ( 3881.823 - max(0, 1802.23 - 7526.045+3881.823))
=8613.838

Beijing Wantai Biological Pharmacy Enterprise Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=73.888 * ( 1 - 25.02% )/( (8613.838 + 8494.608)/ 2 )
=55.4012224/8554.223
=0.65 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14044.057 - 1548.396 - ( 3881.823 - max(0, 1802.23 - 7526.045+3881.823))
=8613.838

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13760.997 - 1305.663 - ( 3960.726 - max(0, 1598.065 - 6730.936+3960.726))
=8494.608

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.65% mean?
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a ROC % of 0.65% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors.
Is Beijing Wantai Biological Pharmacy Enterprise Co's ROC % too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current ROC % is 0.65%. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's ROC % compare to VRTX and REGN?
Beijing Wantai Biological Pharmacy Enterprise Co's ROC % of 0.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current ROC % is 0.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥42.09, compared to a current price of ¥29.20 — trading 30.6% below its estimated fair value. The current ROC % is 0.65%. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current ROC % is 0.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued. The current stock price of ¥29.20 is trading 30.6% below its estimated GF Value™ of ¥42.09. GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.

Key valuation signals for SHSE:603392:

  • ROC %: 0.65%
  • GF Value™: ¥42.09 vs. price of ¥29.20 (30.6% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Wantai Biological Pharmacy Enterprise Co Business Description

Address No. 31, Science Park Road, Changping District, Beijing, CHN, 102206
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score

Get the complete analysis for SHSE:603392

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.20
Price
¥42.09
GF Value